BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28

• Endo Pharma Issues Voluntary Nationwide Recall For One Lot Of Edex (Alprostadil For Injection) 10 Mcg 2 Pack Carton Due To Potential Lack Of Sterility Assurance

  February 27, 2017

   · 

  3 min read
• Drug Development

  Mederi Therapeutics Inc. Release: Landmark Study: Meta-Analysis Of 28 Studies Shows Stretta Therapy For GERD Consistently And Significantly Improves Outcomes

  February 27, 2017

   · 

  3 min read
• Drug Development

  Study Of SanBio, Inc.'s Stem Cell Treatment For Stroke Receives Innovation Award From AHA

  February 27, 2017

   · 

  2 min read
• FDA

  BTG plc Snags FDA Clearance for Blood Clot Device EKOS Control Unit 4.0

  February 27, 2017

   · 

  5 min read
• Policy

  Bausch & Lomb And NicOx SA Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod

  February 27, 2017

   · 

  5 min read
• Drug Development

  OncoSec Medical Granted FDA Fast Track Designation For Immunopulse IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab

  February 27, 2017

   · 

  5 min read
• Drug Development

  AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

  February 27, 2017

   · 

  8 min read
• Drug Development

  RegeneRx Biopharmaceuticals, Inc. Licensee Receives FDA Permission To Conduct A Phase III Trial Of RGN-137 For Epidermolysis Bullosa In U.S.

  February 27, 2017

   · 

  5 min read
• Pharma Two B Ltd. Closes $30 Million Financing Round

  February 27, 2017

   · 

  4 min read
• Drug Development

  Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I

  February 27, 2017

   · 

  4 min read